Maloof Ventures launches Never Hungover
LOS ANGELES — Maloof Ventures announced on Friday the launch of Never Hungover at GNC. Never Hungover is a dietary supplement that is comprised of a natural vitamin blend, antioxidants, amino acids, nutrients and minerals packaged as a 2-oz. serving.
The hangover shot is designed to take up to an hour before or while consuming alcohol, and experiences optimal results when taking one bottle per four drinks.
"My family and I believe that Never Hungover is an exceptional product that will benefit anyone who uses it, and we are very excited to launch this brand with such an influential health-and-wellness leader as GNC," stated Gavin Maloof, Maloof Ventures and Never Hungover co-owner.
Manufactured in America, Never Hungover retails for $3.99.
Harvard Heart Letter: Many consumers who supplement with aspirin don’t need to
BOSTON — Fewer than half of people who could benefit from the heart-health benefits of a daily low-dose aspirin take it, while many others take it when they shouldn’t, the January 2014 Harvard Heart Letter reported Friday.
If you don’t have heart disease, but do have high blood pressure, diabetes or other risk factors for heart disease, don’t automatically assume that taking aspirin every day is a good idea, the Letter noted. "A lot of people take aspirin who really shouldn’t," stated Christopher Cannon, a cardiologist at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School. "Everyone assumes aspirin is harmless, but it isn’t."
For some, the downsides of aspirin — mainly gastrointestinal bleeding — outweigh its benefits. Taking aspirin with food may help. So can taking medications to treat heartburn, which help protect the stomach. These include simple antacids like Tums, acid blockers like famotidine (Pepcid) or proton-pump inhibitors, such as omeprazole (Prilosec OTC, Zegerid OTC).
A pill that combines aspirin and omeprazole may soon be available, the Letter suggested.
FDA advisory committee to consider OTC NDA for asthma-relieving Primatene HFA
SILVER SPRING, Md. — The Nonprescription Drugs Advisory Committee on Thursday announced it would meet February 25 to discuss data submitted by Armstrong Pharmaceuticals in support of a new drug application for the over-the-counter marketing of Primatene HFA, an epinephrine inhalation aerosol 125 microgram (mcg)/actuation, as a temporary reliever of mild symptoms of intermittent asthma for consumers 12 years of age and older.
The epinephrine inhaler was developed as a replacement for Primatene Mist (epinephrine metered inhaler 200 mcg/actuation), an OTC product that was phased out in December 2011 because of the use of chlorofluorocarbons as the propellant.
The committee will be asked to consider whether the data support an acceptable risk/benefit profile of the epinephrine inhaler for use by OTC consumers.
The following day, the committee will meet to discuss whether OTC bronchodilators administered by hand-held rubber bulb nebulizers for the temporary relief of mild symptoms of intermittent asthma (shortness of breath, tightness of chest, and wheezing) should be removed from the monograph altogether. Specific drugs to be discussed include epinephrine, epinephrine bitartrate and racepinephrine hydrochloride.